Immunoregulatory functions and the therapeutic implications of GARP-TGF-β in inflammation and cancer

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters

| Citation | Metelli, Alessandra, Mohammad Salem, Caroline H. Wallace, Bill X. Wu, Anqi Li, Xue Li, and Zihai Li. 2018. “Immunoregulatory functions and the therapeutic implications of GARP-TGF-β in inflammation and cancer.” Journal of Hematology & Oncology 11 (1): 24. doi:10.1186/s13045-018-0570-z. http://dx.doi.org/10.1186/s13045-018-0570-z. |
| Published Version | doi:10.1186/s13045-018-0570-z |
| Citable link | http://nrs.harvard.edu/urn-3:HUL.InstRepos:35014949 |
| Terms of Use | This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA |
Immunoregulatory functions and the therapeutic implications of GARP-TGF-β in inflammation and cancer

Alessandra Metelli, Mohammad Salem, Caroline H. Wallace, Bill X. Wu, Anqi Li, Xue Li and Zihai Li

Abstract

GARP (glycoprotein-A repetitions predominant) is a type I transmembrane cell surface docking receptor for latent transforming growth factor-β (TGF-β) that is abundantly expressed on regulatory T lymphocytes and platelets. GARP regulates the availability of membrane-bound latent TGF-β and modulates its activation. For this reason, GARP expression on immune and non-immune cells is involved in maintaining peripheral tolerance. It plays an important role in preventing inflammatory diseases such as allergy and graft versus host disease (GVHD). GARP is also frequently hijacked by cancer cells to promote oncogenesis. This review summarizes the most important features of GARP biology described to date including gene regulation, protein expression and mechanism in activating latent TGF-β, and the function of GARP in regulatory T cell biology and peripheral tolerance, as well as GARP’s increasingly recognized roles in platelet-mediated cancer immune evasion. The promise for GARP-targeted strategy as a novel immunotherapy of cancer is also highlighted.

Keywords: TGF-β, GARP, Treg, Immune tolerance, Cancer, Platelets

Background

Transforming growth factor-β (TGF-β) is a pleiotropic cytokine expressed by the majority of cells and found in all tissues [1]. It plays important roles in numerous aspects of biological processes such as cell proliferation, development, apoptosis, fibrosis, angiogenesis, wound healing, cancer, and much more [2–4]. TGF-β’s production and secretion consist of a series of tightly regulated steps, as any dysregulation can lead to disease [5, 6]. Biochemically, TGF-β exists in at least four different forms: (1) freely soluble TGF-β; (2) soluble TGF-β associated with latency-associated peptide (LAP), known as latent TGF-β (LTGF-β); (3) TGF-β-LAP-LTBP, latent TGF-β associated with latent TGF-β-binding protein (LTBP); and (4) membrane-associated latent form of TGF-β [7, 8]. Three isoforms of TGF-β exist, TGF-β1, TGF-β2, and TGF-β3, encoded by three different genes; yet, TGF-β1 is the most studied among the three [9, 10].

Glycoprotein-A repetitions predominant protein (GARP) has emerged as a critical regulator of latent TGF-β activation [11–14]. By binding to LTGF-β, GARP acts as a docking receptor that concentrates LTGF-β on the cell surface and enhances its final activation [15]. The function of GARP has been extensively studied on regulatory T lymphocytes (Tregs), where it complexes with αVβ8 integrins to release active TGF-β from the surface of the cells [16, 17]. Via this function, GARP was shown to be involved in enhancing the suppressive phenotype of Tregs and in maintaining Treg-mediated peripheral tolerance [12, 18, 19]. Since the discovery of GARP in 1992 [20], the scientific literature regarding GARP can be divided into three consecutive time periods; each of them emphasizes research on a specific aspect of the protein (Fig. 1). Initially, GARP gained attention between 1992 and 2006 because of its gene amplification in aggressive forms of human metastatic carcinomas [21–23]. Subsequently, GARP was identified as a latent TGF-β1 receptor expressed on immune cells, specifically on Tregs and megakaryocytes/platelets [15]. At this time, GARP was identified as a Treg activation marker and for its ability to regulate the bioavailability of TGF-β [11]. During the last...
3 years, several new aspects of GARP have been discovered. For example, our recent findings established a strong connection between GARP and cancer by describing the pro-tumorigenic function of this protein in several human malignancies [14] and the unexpected role of platelet GARP in immune evasion and the cancer progression [24]. Moreover, GARP expression has been recently described on human B cells in response to B cell receptor activation and Toll-like receptor (TLR) 9 ligation [25] (Caroline Wallace and Zihai Li, unpublished).

**GARP: gene and protein structure**

**Lrrc32 gene**

In their studies on gene amplification, Ollendorff and colleagues identified a new independent unit designated D11S833E in the telomeric region at 11q13-q14, which they named GARP [20, 26]. In situ hybridization studies revealed that the murine Lrrc32 gene is localized on chromosome 7 in a region that is conserved between human and murine genome [20]. Interestingly, Lrrc32 gene locus is part of a chromosomal region frequently altered in human cancers [27]. Indeed, Lrrc32 specific gene amplification was observed in human breast cancer [28] and primary and metastatic neck lymph nodes in oral squamous cell carcinoma [22]; moreover, in prostate cancer, Lrrc32 amplification rate increases with the decrease of hormone sensitivity [23]. Conversely, deletion and rearrangement of Lrrc32 locus were described in two cases of hibernoma, thus unveiling the ambiguous behavior of Lrrc32 gene product in human malignancies [29]. Nucleotide blasting analysis showed that human and murine Lrrc32 gene have a similar structure, i.e., they share 81% of homology and both comprise of two coding exons; in particular, the first exon encodes for the signal peptide and nine amino acids, and the second exon encodes for the majority of the coding region [30].

**GARP gene regulation**

Upon T cell receptor (TCR) engagement, GARP expression is induced in Tregs; no significant surface expression of GARP has been described in human or mouse conventional T helper (Th) cells [31]. Haupt and colleagues discovered that cell and context-specific expression of the GARP gene is the result of the interplay of two alternative promoters: upstream promoter 1 (P1) and downstream promoter 2 (P2). Both promoters drive GARP gene transcription; however, the variance in their methylation status in different cell populations dictates where, and under what conditions, GARP will be expressed. P2 is almost completely demethylated in both Tregs and Th cells, yet only in Th cells is the transcription initiation from P2 blocked by several methylated CpG islands present in the downstream P1. Also, by inhibiting binding with transcription factors, the methylated CpGs maintain P1 in a closed chromatin configuration. In contrast, the less pronounced methylation status of P1 in Tregs allowed the binding of its nuclear master transcription factor forkhead box P3 (FoxP3) that remodels the promoter region toward an open configuration status. This allows the subsequent binding of nuclear factor of activated T cells (NFAT) and nuclear factor-κB (NF-κB) to drive the transcription of the GARP gene [32]. A clear example of this FoxP3-mediated GARP expression is the conversion of tumor-specific Th17 cells to ex-Th17 FoxP3+ cells that show upregulation of surface GARP as a transdifferentiation-associated marker [33]. Accordingly, knocking-down of FoxP3 with
RNA interference in Tregs reduced surface GARP, yet GARP silencing did not affect FoxP3 expression [34]. Tregs are not the only cell population that experiences GARP-FoxP3 co-regulation; human and murine megakaryocytes and platelets constitutively express both FoxP3 and the surface GARP/LAP complex. Interestingly, upon activation, platelets upregulate both GARP and FoxP3: protease-activated receptor 4 activating peptide (PAR4-AP) increases surface GARP, while phorbol ester myristate acetate upregulates FoxP3 expression [15, 35, 36]. Although the simultaneous upregulation of GARP and FoxP3 needs to be demonstrated, these findings suggest that platelets are another subset of cellular entities where GARP and FoxP3 interdependence might occur. In addition to lymphocytes and platelets, human melanocytes simultaneously express FoxP3 and GARP [37], further demonstrating this association.

Even though many reports are in favor of FoxP3 and GARP co-expression, other reports suggest that expression of FoxP3 and GARP is independent of each other. For example, while FoxP3 shRNA affects GARP expression, GARP shRNA does not change FoxP3 expression in expanded Tregs [34]. Furthermore, Helios, but not FoxP3, has been described as the marker of activated Tregs expressing GARP/LAP [38]. Additionally, GARP is inducible on activated human CD19+CD20+ B cells through B cell receptor (BCR) and TLR 9 engagement by anti-immunoglobulin (Ig) M antibodies and unmethylated bacterial DNA (CpG), respectively, where it enhances class switching recombination and production of IgA [25] (Caroline Wallace and Zihai Li, unpublished). Based on this last observation, it is reasonable to hypothesize that TLR signaling induces GARP expression via NF-κB, since GARP promoter has a putative NF-κB binding region as previously mentioned. All these reports indicate that the interdependence of GARP and FoxP3 expression remains an intriguing area that is far from being completely understood [38].

In addition to FoxP3, signal transducer and activator of transcription 3 (STAT3) is another transcription factor that was found recently to regulate GARP gene expression; Interleukin (IL)-6 administration to CD4+ naïve T cells is sufficient to restrain GARP transcription and expression via the STAT3 signaling pathway [39]. As will be discussed later, GARP is a latent TGF-β receptor that enhances furin-mediated pro-TGF-β cleavage, yet the expression of GARP per se is independent of both TGF-β and Furin [40].

Post-transcriptional regulation is another important checkpoint in GARP expression. The distal part of the 3′ untranslated region (UTR) of GARP transcript is targeted by six microRNAs (miRNAs) which decrease GARP protein expression. Among these six microRNAs, miR-142-3p is expressed 2.5 times more in Th cells than in Tregs, and upon TCR stimulation, miR-142-3p expression decreases in both T cell populations [41]. MiR-142-3p facilitates the formation of a complex that together with argonaute 2, and GARP-mRNA controls GARP expression via post-transcriptional regulation [42].

**GARP protein**

After gene isolation, human and mouse GARP protein putative sequences were deciphered. GARP protein is a type I transmembrane protein and can be divided into three domains: the extracellular domain, which constitutes approximately 70% of the protein; the hydrophobic transmembrane domain; and the 15 amino acid residue cytoplasmic tail (Fig. 2). As part of the leucine-rich repeats (LRR)-containing proteins family, the extracellular domain of GARP contains 20 LRR motifs, divided into two groups by a proline-rich region, and a C-terminal LRR (LRRCT) [26, 30]. Among the extracellular LRR proteins, GARP, together with TLRs, glycoprotein 1bα and glycoprotein 1bβ, belongs to the LRR Tollkin sub-family, a group of proteins involved in inflammation [43]. Like TLRs, Zhang et al. showed that GARP requires the master chaperone gp96 (GRP94) in the endoplasmic reticulum for its folding and surface expression [44, 45]. The proline-rich region located between the LRR of GARP resembles the hinge domain of the LTBP. This
domain confers flexibility to the protein and suggests that GARP might be involved in protein-protein interaction [46, 47]. Additionally, like LTBP, GARP covalently disulfide links with LAP; site-specific mutagenesis from Cys to Ala demonstrated that Cys-192 and Cys-331, located on the 7th and 12th LRR respectively, are responsible for the disulfide linkage between GARP and Cys-4 of LAP [11]. Despite the high homology in the extracellular domain, murine and human cytoplasmic tails show a 33% difference in the amino acid sequence, yet they both have a conserved tyrosine residue. Of interest, other members of LRR_Tollkin family, like TLRs, have a cytoplasmic phosphorylated tyrosine involved in signal transduction, suggesting a possible tyrosine phosphorylation-dependent function for GARP [48].

**Tissue distribution and cell type-specific expression**

In human tissues, GARP is expressed in the peripheral blood, placenta [49], and pancreas [50]. In accordance with the mRNA expression data, GARP protein is expressed by human breast cancer, lung cancer, and colon cancer cells, where higher GARP expression correlates with worse clinical outcome [14]. GARP expression has been reported in multiple human and mouse cells—specifically on human activated B cells [25] (Caroline Wallace and Zihai Li, unpublished), human and mouse mesenchymal stromal cells [51], Tregs [15], megakaryocytes/platelets [52], hepatic stellate cells [53], and mouse LAP+ γδ T cells [54]. GARP is widely expressed in the mouse lymphoid organs, including the thymus as well as the Peyer’s patches [40]. This is not surprising because GARP-expressing Tregs are abundantly present in these sites. We recently demonstrated that GARP is strategically expressed on the median edge epithelial cells of the palate shelf during embryogenesis, where it is critical for TGF-β3 activation and signaling, and is thus indispensable for normal palatogenesis [55]. We showed that whole-body Lrxc32-null mice do not survive 24 h after birth as a result of the defect in the fusion of the palatal shelves, a phenotype indistinguishable from the Tgfb3-null mice [56].

The presence of soluble GARP as a result of shedding from T cell membrane has also been reported [41]. The possibility of a shedding process was first discussed by Roubin and colleagues in 1996 when, describing a GARP deduced amino acid sequence, they observed the presence of a hydrophobic leader sequence. They hypothesized that this domain might be the signal peptide for targeting the protein to the secretory pathway [30]. Soluble GARP indeed is present in human plasma [57], yet the mechanism and significance of the protein’s shedding or secretion is not clear.

**GARP function in TGF-β maturation and activation**

GARP is expressed on the cell surface where it was thought initially to be the docking receptor only for latent TGF-β1 [58]. Of interest, the association with GARP is not uniquely limited to latent TGF-β1; latent TGF-β2 binds to GARP with a much lower binding affinity [15]. Importantly, the genetic and biochemical evidence demonstrated that GARP is absolutely required for the association to and activation of latent TGF-β3 [55]. Thus, GARP can bind to all three TGF-β isoforms.

As a very powerful cytokine, sometimes referred to as a “beast” [59], TGF-β production and secretion consist of multiple tightly regulated steps; interestingly, GARP plays a role in each of them (Fig. 3). First, TGF-β is synthesized and secreted through the secretory pathway as inactive homodimeric pro-proteins that are cleaved by furin-type proteases to generate a mature TGF-β. At this stage, the newly synthesized molecule is both covalently (through disulfide bonds) and non-covalently associated with LAP, referred to as latent TGF-β [10]. A study from Sophie Lucas’ laboratory demonstrated that GARP increases the rate of pro-TGF-β cleavage in a furin-independent manner [41].

Subsequently, latent TGF-β associates with the LTBP, creating the large latent complex (LLC) [60]. GARP can interfere with this association due to its higher binding affinity to latent TGF-β; when both GARP and LTBP are co-expressed in 293 T cells, GARP outcompetes LTBP for latent TGF-β binding. Interestingly, electron microscopy analysis showed that GARP and latent TGF-β association also can be mediated by non-covalent binding [11]. The nature and function of this weakly associated complex might mediate TGF-β activation upon surface shedding [61], as discussed below.

Finally, the release of the biologically active mature TGF-β requires the separation and release of the mature form of TGF-β from the LAP. Multiple mechanisms have been evoked to describe this critical step, where cell surface integrins are the main orchestrators. αVβ6 and αVβ8 can activate latent TGF-β through protease-dependent and protease-independent mechanisms. In the protease-independent manner, αVβ6 and αVβ8 integrins bind to the latent TGF-β and, after deforming the surface LAP, they mediate the release of the mature form of TGF-β. In the protease-dependent mechanisms, integrins recruit metalloproteinases or serine proteases that cleave LAP and, subsequently, liberate TGF-β [62, 63]. For example, thrombin mediates the activation of latent TGF-β bound to αVβ6 in a murine pulmonary injury model [64]. Recent findings demonstrated that membrane-bound GARP facilitates the protease-
independent TGF-β activation via the formation of a complex together with αVβ6 integrins and latent TGF-β. Intriguingly, the association of the GARP/latent TGF-β complex with integrins does not disrupt the ring-like structure of the pro-TGF-β, suggesting that the integrin interaction is essential, yet it is not sufficient for secretion of mature TGF-β [11]. This may indicate that similarly to latent TGF-β alone, integrin binding to LAP predisposes the complex for the release of the active peptide; however, extra tensile force is required for the removal of the "straightjacket" elements of LAP [65]. This might explain why active TGF-β released from GARP/latent TGF-β complex is not always detectable, yet it is still able to activate TGF-β signal transduction, as shown in Tregs [12], B cells [25], and some TGF-β reporter cell lines [11].

Integrin contribution has also been described for activated Tregs; αVβ8 integrins are responsible for the release of latent TGF-β from the cell surface and for the formation of biologically active TGF-β as indirectly measured by Th17 induction [16]. Recent studies indeed demonstrated that on the Treg surface, GARP relies on the interaction with αVβ8 integrins to release active TGF-β [17]. Intriguingly, integrins and membrane tensile forces do not explain the release of mature TGF-β from soluble GARP (sGARP). This conundrum was partially unveiled by Fridrich and colleagues when they observed that mature TGF-β can be released from sGARP only when GARP and latent TGF-β are non-covalently associated [61]. However, the underlying mechanism is still obscure.

**GARP and peripheral immune tolerance**

As discussed above, the GARP promoter has a binding site for FoxP3, indicating that Treg-specific transcription factor is required for GARP expression. Accordingly, silencing FoxP3 in human Tregs reduces surface GARP upon TCR stimulation [34]. On the other hand, enforced GARP expression in human Th cells endows cells with suppressive capability by upregulating several Treg and TGF-β signature genes including FoxP3, CD25, and CTLA4 [31, 66]. These findings suggest that the tolerogenic Treg phenotype might be reinforced by a positive feedback loop between GARP and FoxP3. Accordingly, in Treg cells that are differentiated in vitro, silencing of GARP partially impairs their suppressive ability [34]. In this regard, we demonstrated that mice lacking surface GARP on Tregs, due to a Treg-specific deletion of a molecular chaperone gp96, developed a fatal multi-organ inflammatory disease [44]. In these mice, indeed, GARP folding and surface expression were completely abrogated, thus preventing the formation of GARP/LTGF-β...
complex on activated Tregs and consequently the acquisition of the suppressive phenotype. Thus, gp96 deletion abolished the expression of cell surface GARP-LTGF-β as well as the mechanism of LTGF-β activation. Accordingly, this fatal phenotype can be partially rescued by exogenous active TGF-β administration [44]. It is noteworthy to mention that gp96 serves as a chaperone for numerous client proteins such as TLRs [67, 68] and multiple α and β integrin subunits [45, 69, 70], indicating that the inflammatory phenotype observed in Treg-specific gp96-deficient mice cannot be attributed to GARP deletion alone. Indeed, it has been recently shown that the final release of TGF-β from the GARP-LTGF-β complex requires the interaction of the complex with αVβ8 integrins, which are also chaperoned by gp96 [71].

The tolerogenic roles of GARP might give a mechanistic explanation for atopic dermatitis manifested by patients with gene mutations in the Lrrc32 gene locus that prevents GARP surface expression [72]. Conversely, other reports indicate that FoxP3 is not required for GARP expression on T cells upon TCR stimulation and that FoxP3+ Tregs maintain the same suppressive phenotype even in the absence of GARP [40].

The importance of GARP in peripheral tolerance is also indicated by the results of meta-analyses of genome-wide association studies which showed a strong correlation between Lrrc32 gene locus expression and conditions like Crohn’s disease, ulcerative colitis [73], and allergic diseases [74]. In line with the findings of the genome-wide association studies, sGARP has been proven to be useful as an anti-inflammatory therapeutic agent by sustaining Treg immune-modulatory activity in a xenogeneic graft versus host disease (GvHD) model and in an allergen-specific gut inflammation system [19, 75]. In addition, allergic airway inflammation is mitigated by sGARP administration in a TGF-β-dependent manner [18]. On the other hand, Eschborn and colleagues showed that, while sGARP mitigates allergen-specific gut inflammation, injections of anti-GARP blocking antibody reduce the therapeutic effect of activated Tregs [75]. Additionally, blocking IL-6 signaling in the presence of TGF-β polarized Tregs to high GARP and LAP expression which are able to maintain oral tolerance in a delayed type hypersensitivity (DTH) model [39]. Furthermore, monoclonal GARP/latent TGF-β antibody blocks the autocrine production of active TGF-β in Tregs, restraining their immunosuppressive activity in a xenogeneic model of GvHD [12].

GARP and cancer immune evasion

Although GARP offers an important protective role for the host in inflammation-driven pathological conditions, the tolerogenic FoxP3/GARP/TGF-β axis is a mediator of the immunosuppressive microenvironment that enhances tumor growth. For example, human ovarian cancer ascites are infiltrated with FoxP3+GARP+ Treg cells [33]. Higher frequency of GARP+FoxP3+ expression in Tregs positively correlates with an elevated immunosuppressive and more aggressive phenotype in advanced hepatocellular carcinoma [76].

As suggested by Lrrc32 gene amplification, GARP protein is expressed on human cancer cells where it mediates the accumulation and subsequent activation of the circulating latent TGF-β [14]. GARP supports cancer cell growth and dissemination by providing an excellent reservoir of TGF-β that functions in the tumor microenvironment (TME) by regulating the innate and adaptive immune components and favoring tumor immune evasion. With regard to innate immunity, TGF-β inhibits natural killer (NK) cells and dendritic (DC) cells maturation [77, 78]. The role of TGF-β is also well studied in the non-resolving inflammation that facilitates cancer initiation [79, 80]. Tumor-derived TGF-β polarizes macrophages into tumor-associated macrophages (TAM) [81]. This cell population is a cancer therapeutic target because of its secretion of pro-inflammatory cytokines like IL-6, IL-23, and IL-17. Additionally, TGF-β derived from TAMs is one of the major drivers of the epithelial to mesenchymal transition [81–83]. Furthermore, tumor-derived TGF-β drives the formation of cancer-associated fibroblasts (CAFs), which in turn exert a strong pro-tumorigenic activity on epithelial cells by secreting their own TGF-β [84]. CAFs’ pro-tumorigenic properties have been reported for many malignancies such as prostate cancer [85], non-small cell lung carcinoma [86], and colorectal carcinoma [87]. Similarly, TGF-β impairs the adaptive anti-tumor immunity by directly inhibiting the clonal expansion and cytotoxicity of the CD8+ cytotoxic T cells (CTLs) [88, 89]. Finally, TGF-β indirectly attenuates CTLs by inducing the expression of Foxp3, which confers a regulatory and immune suppressive phenotype to CD4+ T cells [90].

Human malignant melanocytes express and secrete membrane-bound GARP and sGARP, respectively, that skew macrophages toward a polarized M2 phenotype and constrain the proliferation CTLs and their ability to produce cytokines [37]. In addition, GARP has been found to be highly expressed in human breast, colon, and lung cancers where GARP/TGF-β axis sustains primary tumor growth and distant metastasis. Intriguingly, a monoclonal antibody that blocks the binding between latent TGF-β and GARP was shown to be effective therapeutically in a murine syngeneic mammary carcinoma model [14]. Beyond blocking the GARP and latent TGF-β interaction on tumor cells, novel antibody-based strategies are emerging to block GARP/latent TGF-β complex on the surface of Tregs, thus preventing the secretion of active TGF-β. As reported above, a monoclonal human GARP antibody produced and tested in Sophie Lucas’ laboratory has been
shown to inhibit the immunosuppressive activity of Tregs by blocking GARP in complex with latent TGF-β [12]. Although the efficacy of this antibody was tested on xenogeneic GvHD, the authors suggested that this antibody might be useful for cancer immunotherapy, a notion that remains to be tested. In line with this consideration, however, LAP blocking antibody has been proven to reduce tumor growth in animal models of melanoma, colorectal carcinoma, and glioblastoma by decreasing the number of GARP’LAP’ Tregs [91].

Albeit the role that GARP plays on cancer cells and on Tregs has been carefully studied, more research is required to understand how the cancer cells induce GARP expression and influence its function. The only stimuli described until now that trigger surface GARP are the BCR and TLRs engagement on human CD19+CD20+ B cells [25] (Caroline Wallace and Zihai Li, unpublished). This finding in combination with the study on the regulation of GARP promoter [32] might suggest that GARP expression requires the engagement of the MyD88 and NF-kB pathway. It is well known that chronic inflammation sets the stage for cancer development by triggering NF-kB signaling in immune and non-immune cells [92]. In this regard, it is interesting to notice that many cancers upregulate surface receptors to amplified NF-kB signaling as a surviving mechanism. For instance, in ovarian cancer, TLR2 [93] and lysophosphatidic acid (LPA) receptor [94] are associated with cancer stem cell renewal and cell invasion, respectively. The sustained NF-kB signaling might be one mechanism exploited by cancer cells to induce surface GARP expression. However, this hypothesis needs to be tested.

**Platelet GARP**

As mentioned previously, GARP protein was first identified on activated Tregs and platelets [15]. Despite the increasing knowledge about the role of GARP in Tregs, little attention has been paid until recently to the role of GARP on platelets [24]. It is not entirely clear whether GARP plays a role in platelet activation and function since two different studies in two different animal models describe conflicting findings. The first study performed in *Danio rerio* (zebrafish) demonstrated that GARP is important for thrombus initiation and hemostasis; knockdown of the *Lrrc32* gene resulted in increased spontaneous bleeding events [95]. A second study, performed in a genetic mouse model where *Lrrc32* is specifically knocked out from platelets and megakaryocytes, shows that GARP is not necessary for thrombus formation and clot retraction, which is also confirmed by our own unpublished observations. Interestingly this last study shows that ex vivo platelet activation triggers increase in GARP surface expression, indicating that GARP might play a role in activating platelets [35]. Using the same platelet-specific GARP knockout mouse model, we recently demonstrated that GARP enhances the activation of latent TGF-β released by platelets [24]. Serum active TGF-β was drastically reduced in these mice, and interestingly, the similar phenotype was not observed in mice with platelet-specific deletion of *Tgfb1* gene, indicating that platelet GARP activates latent TGF-β1 secreted by cells other than by platelets [24]. Importantly, the same study demonstrated that the platelets contribute dominantly to the activity of TGF-β in the tumor environment. Among platelet-derived soluble factors, TGF-β is one of the main mediators for the platelet-dependent tumor growth [96, 97], which was once again confirmed by an unbiased biochemical and biophysical strategy [24]. Accordingly, platelet-specific deletion of GARP potentiated protective immunity against both murine models of melanoma and colon cancer [24]. This study also provides a mechanistic explanation as to why thrombocytopenia is consistently associated with poor outcome in cancer [98]. Intriguingly, blocking platelet activation pharmacologically with aspirin and clopidogrel was shown to significantly enhance the adoptive T cell therapy of murine melanoma [24], which correlated with increased persistence and functionality of transferred donor T cells. This study lays a strong foundation for combining anti-platelet agents and immunotherapy as a novel strategy for cancer care in the future.

Beyond TGF-β, each activated platelet releases up to 80 α-granules secreting platelet-derived growth factors (PDGFs) in the tumor proximity which contribute to the platelet-cancer interaction [96, 99]. Activated platelets, for example, secrete vascular endothelial growth factor (VEGF) that induces angiogenesis and cell migration [100]. Additionally, multiple inflammatory cytokines are released by activated platelets such as IL-1, IL-6, granulocyte macrophage colony stimulating factor (GM-CSF) [101], and CD40L [102]. It is not known whether GARP plays a role in the release and/or activation of any other growth factor or cytokines produced by active platelets other than TGF-β, this intriguing possibility deserves further investigation.

**Conclusions and future perspective**

Cancer immunotherapy, including the PD-1/PD-L1 immune checkpoint-targeted strategy, represents an exciting paradigm shift in oncology which aims to treat the immune system and not the cancer per se [103, 104]. A combination strategy with checkpoint inhibitors and other immune intervention is being pursued to overcome the resistance and lack of responsiveness observed in a majority of patients. GARP is a docking receptor for latent TGF-β and is involved in its activation. The function of GARP-TGF-β in Treg biology has been a topic of increasing interest. More recently, the tolerogenic roles of GARP expression by cancer cells and platelets have gained attention due to the belief that GARP represents an attractive
target, either alone or in combination with immune checkpoint blockers, for cancer immunotherapy. Blocking the GARP-latin TGF-β complex on Tregs represents two possible advantages compared to the other strategies that either block TGF-β [106–107] or deplete Tregs with anti-CD25 antibody [108]. Blocking TGF-β systemically could cause undesired consequences due to the pleiotropic roles of this cytokine. GARP is mainly expressed by tumor cells, Tregs, and platelets present in the TME. Thus, targeting GARP has the advantage of blocking TGF-β activation only where it plays a pro-tumorigenic role. Since effector T cells express CD25 but not GARP, GARP-based depletion of Tregs shall be more advantageous over CD25-targeted approach [109]. However, any GARP-targeted strategy must be preceded with caution to not compromise the number and function of platelets.

For GvHD, reactive airway diseases or other inflammatory conditions, soluble GARP might find its role as a novel therapeutic agent. The full potential of the GARP-targeted strategy awaits more fundamental studies of GARP biology in relation to its biochemistry, cancer biology, and immunology. The strategic importance for GARP to be expressed by platelets in immune tolerance calls for further study of platelets, the last cellular entity in the blood to be discovered, in a wide range of diseases including their underappreciated roles in cancer immune evasion.

**Acknowledgements**

The authors thank the current members of the Zihai Li laboratory for stimulating the discussion on the topic.

**Funding**

This work was supported by multiple NIH grants CA186866, CA213290, CA188419, and AI077283 (to ZL) and Hollings Cancer Center’s Cancer Center Support Grant P30CA138313. ZL is the Abney Scholar for Stem Cell Biology and Therapy and is supported by the South Carolina SmartState Center of Excellence.

**Availability of data and materials**

The material supporting the conclusion of this study has been included within the article.

**Authors’ contributions**

AM completed the first draft of the manuscript, and all other authors provided critical input for the finalization of the manuscript. ZL supervised the project and provided critical guidance. All authors read and approve the final manuscript.

**Ethics approval and consent to participate**

This is not applicable for this study.

**Consent for publication**

The authors have consented fully for the publication of this manuscript.

**Competing interests**

The authors declare that they have no competing interests.

**Publisher’s Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Author details**

1Department of Microbiology and Immunology, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC 29425, USA. 2Children’s Hospital Boston, Harvard Medical School, Boston, MA 02115, USA. 3The First Affiliated Hospital, Zhengzhou University School of Medicine, Zhengzhou 450052, China.

**Received:** 3 January 2018 **Accepted:** 6 February 2018

**Published online:** 20 February 2018

**References**

1. Li MO, Wan YJ, Flavell RA. T cell-produced transforming growth factor-beta1 controls T cell tolerance and regulates Th1- and Th17-cell differentiation. Immunity. 2007;26(5):579–91.
2. Gordon KJ, Böbe GC. Role of transforming growth factor-beta superfamily signaling pathways in human disease. Biochim Biophys Acta. 2008;1782(4):197–226.
3. Kulkarni AB, Karlsson S. Transforming growth factor-beta 1 knockout mice. A mutation in one cytokine gene causes a dramatic inflammatory disease. Am J Pathol. 1993;143(1):3–9.
4. Li MO, Wan YJ, Sanjabi S, Robertson AK, Flavell RA. Transforming growth factor-beta regulation of immune responses. Annu Rev Immunol. 2006;24:149–166.
5. Zhu HJ, Burgess AW. Regulation of transforming growth factor-beta signaling. Mol Cell Biol Res Commun. 2001;4(6):321–30.
6. Kelly A, Saada SA, Sherwood E, Casulli J, Travis MA. Regulation of innate and adaptive immunity by TGFbeta. Adv Immunol. 2017;134:173–233.
7. Meng XM, Nikolic-Paterson DJ, Lan HY. TGF-beta: the master regulator of fibrosis. Nat Rev Nephrol. 2016;12(6):325–38.
8. Kanzaki T, Oltoffson A, Moren A, Wimstedt C, Hellman U, Miyazono K, Claesson-Welsh L, Heldin CH. TGF-beta 1 binding protein: a component of the large latent complex of TGF-beta 1 with multiple repeat sequences. Cell. 1990;61(6):1051–61.
9. Derynck R, Akhurst RJ, Balmain A. TGF-beta signaling in tumor suppression and cancer progression. Nat Genet. 2001;29(2):117–29.
10. Poniatowski LA, WojdaMajewska P, Gask R, Szakiewicz D. Transforming growth factor-beta family: insight into the role of growth factors in regulation of fracture healing biology and potential clinical applications. Mediat Inflamm. 2015;2015:137823.
11. Wang R, Zhu J, Dong X, Shi M, Lu C, Springer TA. GARP regulates the bioavailability and activation of TGFbeta. Mol Biol Cell. 2012;23(6):1129–39.
12. Cuende J, Lienart S, Dedobbeleer O, van der Woning B, De Boeck G, Stockis J, Huygens C, Colau D, Somija J, Delverinne P, Hannon M, Baron T, Dumoutier L, Renaud JC, De Haard H, Saunders M, Coulie PG, Lucas S. Monoclonal antibodies against GARP/TGF-beta1 complexes inhibit the immunosuppressive activity of human regulatory T cells in vivo. Sci Transl Med. 2015;7(128):328ra56.
13. Stockis J, Dedobbeleer O, Lucas S. Role of GARP in the activation of latent TGF-beta1. Mol Biol Syst. 2017;13(10):1925–35.
14. Metelli A, Wu BX, Fuggle OW, Rachidi S, Sun S, Zhang Y, Wu J, Tomlinson S, Howe PH, Yang Y, Garrett-Mayer E, Liu B, Li Z. Surface expression of TGFbeta docking receptor GARP promotes oncosogenesis and immune tolerance in breast cancer. Cancer Res. 2016;76(24):7106–17.
15. Tran DQ, Andersson J, Wang R, Ramsey H, Unutuzd S, Shevach EM. GARP (LRRC32) is essential for the surface expression of latent TGF-beta on platelets and activated FOXP3+ regulatory T cells. Proc Natl Acad Sci U S A. 2009;106(32):13445–50.
16. Edwards JP, Thornton AM, Shevach EM. Release of active TGF-beta1 from the latent TGF-beta1/GARP complex on T regulatory cells is mediated by integrin beta2. J Immunol. 2014;193(6):2843–9.
17. Stockis J, Lienart S, Colau D, Collignon A, Nishimura SL, Sheppard D, Coulie PG, Lucas S. Blocking immunosuppression by human Tregs in vivo with antibodies targeting integrin alphaVbeta3. Proc Natl Acad Sci U S A. 2017; https://doi.org/10.1073/pnas.1710680114.
18. Meyer-Martin H, Hahn SA, Beckert H, Belz C, Heinz A, Jonuleit H, Becker C, Taube C, Korn S, Buhl R, Reuter S, Tuentenberg A. GARP inhibits...
allergic airway inflammation in a humanized mouse model. Allergy. 2016;71(9):1274–83.

19. Hahn SA, Stahl HF, Becker C, Corell A, Schneider FJ, Tuettenberg A, Jonuleit H. Soluble GARP has potent antiinflammatory and immunomodulatory impact on human CD4+ T cells. Blood. 2013;122(7):1182–91.

20. Ollendorff V, Szepetowski P, Mattei MG, Gaudray P, Birnbaum D. New gene in the homologous human 11q13-p14 and mouse 7p chromosomes. Mamm Genome. 1992;3(3):195–7.

21. Szepetowski P, Ollendorff V, Grosgeorge J, Courseaux A, Birnbaum D, Theillet C, Gaudray P. DNA amplification at 11q13.5-p14 in human breast cancer. Oncogene. 1992;7(12):2513–7.

22. Liu CJ, Lin SC, Chang KM, Chang KW. Array-comparative genomic hybridization to detect genome-wide changes in microdissected primary and metastatic oral squamous cell carcinomas. Mol Carcinog. 2006;45(10):721–31.

23. Edwards J, Krishna NS, Witton CJ, Bartlett JM. Gene amplifications associated with the development of hormone-resistant prostate cancer. Clin Cancer Res. 2003;9(14):5271–81.

24. Rachidi S, Mettell P, Aisenberg B, Wu BX, Nelson MH, Wallace C, Paulos CM, Rubinstein MP, Garnett-Meyer E, Hemmig M, Bearden DW, Yang Y, Liu B, Li Z. Platelets subvert T cell immunity against cancer via GARP-TGFbeta axis. Sci Immunol. 2017;2(10):https://doi.org/10.1126/sciimmunol.aal7911.

25. Dedobbeleer O, Stockis J, van der Woning B, Coulie PG, Lucas S. Cutting edge: active TGF-beta1 released from GARP/TGF-beta1 complexes on the surface of stimulated human B lymphocytes increases class-switch recombination and production of IgA. J Immunol. 1997;159(2):391–6.

26. Ollendorff V, Nogales T, Delapeyriere O, Birnbaum D. The GARP gene encodes a new member of the family of leucine-rich repeat-containing proteins. Cell Growth Differ. 1994;5(2):213–9.

27. Schuring E. The involvement of the chromosome 11q13 region in human malignancies: cyclin D1 and EMS1 are two new candidate oncogenes—a review. Gene. 1995;159(1):83.

28. Szepetowski P, Courseaux A, Corell A, Schneider FJ, Tuettenberg A, Jonuleit H, Soluble GARP has potent antiinflammatory and immunomodulatory impact on human CD4+ T cells. Blood. 2013;122(7):1182–91.

29. Maire G, Forus A, Foa C, Johansen B, Ingelsson C, Kresse SH, Myklebost O, Pedersen F. 11q13 alterations in two cases of hibernoma: large deletions and rearrangement breakpoints near GARP in 11q13.5. Genes Chromosomes Cancer. 2003;37(4):389–95.

30. Roubin R, Pizette S, Ollendorff V, Szepetowski P, Mattei MG, Gaudray P, Birnbaum D. New gene linked to BCL1 which can be amplified separately. Oncogene. 1992;7(4):751–7.

31. Probst-Kepper M, Geffers R, Kroger A, Viegas N, Erck C, Hecht HJ, Lunsdorf H. 11q13.5–13.9 breakpoints: a key region in human malignancies: cyclin D1 and EMS1 are two new candidate oncogenes—a review. Gene. 1995;159(1):83.

32. Haupt S, Sontgerath VS, Leipe J, Schulze-Koops H, Skapenko A. Methylation of an intragenic alternative promoter regulates transcription of GARP. Blood. 2003;101(16):5876–83.

33. Garritsen H, Arstila TP, Kekalainen E, Balling R, Hauser H, Buer J, Weiss S. GP96 is a GARP chaperone and controls latent TGF-beta1 production by human regulatory T cells. J Immunol. 2013;190(12):6579–88.

34. Dolan J, Walsh E, Atibury S, Horkap K, O'Keeffe S, Miller SF, Tear G, Mitchell KJ. The extracellular leucine-rich repeat superfamily: a comparative survey and analysis of evolutionary relationships and expression patterns. BMC Genomics. 2007;8:320.

35. Rezende RM, da Cunha AP, Kuhn C, Rubino S, Metelli P. GARP selectively identifies activated human FOXP3+ regulatory T cells. Proc Natl Acad Sci U S A. 2015;112(1):231–41.

36. Chattopadhyay S, Sen GC. Tyrosine phosphorylation in Toll-like receptor signaling. Cytokine Growth Factor Rev. 2014;25(5):533–41.

37. Macaulay IC, Tijssen MR, Thijssen-Timmer DC, Gusnanto A, Steward M, Burns P, Metelli A, Thaxton JE, Hong F, Chiu C, Rubino S, Lin SC, Chang KM, Chang KW. Array-comparative genomic hybridization to detect genome-wide changes in microdissected primary and metastatic oral squamous cell carcinomas. Mol Carcinog. 2006;45(10):721–31.

38. Edwards J, Krishna NS, Witton CJ, Bartlett JM. Gene amplifications associated with the development of hormone-resistant prostate cancer. Clin Cancer Res. 2003;9(14):5271–81.

39. Liu CJ, Lin SC, Chang KM, Chang KW. Array-comparative genomic hybridization to detect genome-wide changes in microdissected primary and metastatic oral squamous cell carcinomas. Mol Carcinog. 2006;45(10):721–31.
TGF-beta 3 indicates defects of epithelial-mesenchymal interaction. Nat Genet. 1995;11(4):415–21.

75. Qian WJ, Monroe ME, Liu T, Jacobs JM, Anderson GA, Shen Y, Moore RJ, Anderson DJ, Zhang R, Calvano SE, Lowry SF, Xiao W, Moldawer LL, Davis RW, Tompkins RG, Camp DG 2nd, Smith RD, Inflammation, the Host Response to Injury Large Scale Collaborative Research P. Quantitative proteome analysis of human plasma following in vivo lipopolysaccharide administration using 16O/18O labeling and the accurate mass and time tag approach. Mol Cell Proteomics. 2005(4):700–9.

76. Stocks J, Colau D, Coullie PG, Lucas S. Membrane protein GARP is a receptor for latent TGF-beta on the surface of activated human Treg. Eur J Immunol. 2006;36(12):3215–21.

77. Robertson IB, Rifkin DB. Unchaining the beast; insights from structural and evolutionary studies on TGFbeta secretion, sequestration, and activation. Cytokine Growth Factor Rev. 2013;24(4):355–72.

78. Annes JP, Munger JS, Rifkin DB. Making sense of latent TGFbeta activation. J Cell Sci. 2003;116(Pt 10):2175–94.

79. Fridrich S, Hahn SA, Linzmaier M, Felten M, Zwarig J, Lenernez V, Tuettenberg A, Stocker W. How soluble GARP enhances TGFbeta activation. PLoS One. 2016;11(4):e0153290.

80. Annes JP, Chen Y, Munger JS, Rifkin DB. Integrin alphaVbeta6-mediated activation of latent TGF-beta requires the latent TGF-beta binding protein-1. J Cell Biol. 2004;165(5):723–34.

81. Mu D, Cambier S, Fiebekingl B, Baron JL, Munger JS, Kawakatsu H, Sheppard D, Broaddus VC, Nishimura SL. The integrin alphaVbeta6 mediates epithelial homeostasis through MT1-MMP-dependent activation of TGF-beta. J Biol Chem. 2002;277(3):493–501.

82. Jenkins RG, Xu S, Gu S, Scotton CJ, Camerer E, Laurent CJ, Davis GE, Chambers RC, Matthy MA, Sheppard D. Ligation of protease-activated receptor 1 enhances alphaVbeta6 integrin-dependent TGF-beta activation and promotes acute lung injury. J Clin Invest. 2006;116(6):1606–14.

83. Shi M, Zhu J, Wang R, Chen X, Mi L, Walz T, Springer TA. Latent TGF-beta structure and activation. Nature. 2011;474(7351):343–9.

84. Wang R, Wan Q, Kozhaya L, Fujii H, Unutmaz D. Identification of a stage-specific subpopulation of liver-derived suppressor cells in hepatocellular carcinoma patients are associated with impaired T-cell functionality. Cancer Res. 2013;73(8):2435–44.

85. Karalith S, Lugade AA, Miller A, Iyer R, Thanavalay Y. Higher frequencies of GARP+CLA+CD4+Foxp3+ regulatory cells and myeloid-derived suppressor cells in hepatocellular carcinoma patients are associated with impaired T-cell functionality. Cancer Res. 2013;73(8):2435–44.

86. Novitskiy SV, Pickup MW, Chytli B, Poloushchikova D, Owens P, Moses HL. Deletion of TGF-beta signaling in myeloid cells enhances their anti-tumorigenic properties. J Leukoc Biol. 2012;92(3):641–51.

87. Sanjabi S, Zenevich LA, Kamaralchi M, Favela RA. Anti-inflammatory and pro-inflammatory roles of TGF-beta, IL-10, and IL-22 in immunity and autoimmunity. Curr Opin Pharmacol. 2009;9(4):447–53.

88. Wang HY. Non-resolving inflammation and cancer. Sci China Life Sci. 2017;60(6):561–2.

89. Yang L, Zhang Y. Tumor-associated macrophages: from basic research to clinical application. J Hematol Oncol. 2017;10(1):58.

90. Grivennikov SI, Wang K, Mucida D, Stewart CA, Schnabl B, Tainguichi K, Yu GF, Osterreicher CH, Hung KE, Datz C, Feng Y, Fearon ER, Okuma M, Tessarollo L, Coppola V, Varofsky F, Cheroutre H, Eckmann C, Trinchieri G, Karin M. Adenoma-linked basal defects and microbial products drive IL-23/IL-17-mediated tumour growth. Nature. 2012;491(7423):254–8.

91. Kong L, Zhou Y, Hu B, Li T, Shi Y, Yang J. Deletion of interleukin-6 in monocytes/macrophages suppresses the initiation of hepatocellular carcinoma in mice. J Exp Clin Cancer Res. 2016;35(1):131.

92. Sutdelle C, Busch J, Tang B, Flanders KA, Osман A, Sutton E, Karpova TS, Roberts AB, Wakfield LM, Niederhuber JE. Transient tumor-fibroblast interactions increase tumor cell malignancy by a TGF-beta mediated mechanism in a mouse xenograft model of breast cancer. PLoS One. 2010;5(3):e9832.

93. Takahashi M, Kimura Y, Yamada K, Somiya H, Nishizuka Y, Ikeda H. The transforming growth factor-beta system in fibroblasts: receptors, activation and mediation of cellular responses. Prog Growth Factor Res. 2013;24(4):355–72.
90. Shevach EM. Mechanisms of foxp3+ T regulatory cell-mediated suppression. Immunity. 2009;30(5):636–45.

91. Gabriely G, da Cunha AP, Rezende RM, Kenyon B, Madi A, VandeVenter T, Skillin N, Rubino S, Garo L, Mazziola MA, Kolypetti P, Lancer AJ, Moreira T, AMC F, Lasmann H, Kuchtoo Y, Murugayyan G, Weiner HL. Targeting latency-associated peptide promotes antitumor immunity. Sci Immunol. 2017;2(11). https://doi.org/10.1126/sciimmunol.aaq1738.

92. Zeligs KP, Neuman MK, Annunziata CM. Molecular pathways: the balance between cancer and the immune system challenges the therapeutic specificity of targeting nuclear factor-kappaB signaling for cancer treatment. Clin Cancer Res. 2016;22(17):4302–8.

93. Chefetz I, Alvero AB, Holmberg JC, Lebowitz N, Craveiro V, Yang-Hartwich Y, Yin Q, Squillace L, Gurrea Soteras M, Aldo P, Mor G. TLR2 enhances ovarian cancer stem cell self-renewal and promotes tumor repair and recurrence. Cell Cycle. 2013;12(3):511–21.

94. Dutta S, Wang FQ, Wu HS, Mukherjee TJ, Fishman DA. The NF-kappaB pathway mediates lysophosphatidic acid (LPA)-induced VEGF signaling and cell invasion in epithelial ovarian cancer (EDC). Gynecol Oncol. 2011;123(1):129–37.

95. O’Connor MN, Salles II, Cwicic A, Watkins NA, Walker A, Gerner SF, Jones CJ, Macaulay IG, Stewart M, Zwaginga JJ, De Roos P, Goodall AH, Deckmyn H, Stemple DL, Ouwehand WH, Bloedorns C. Functional genomics in zebrafish permits rapid characterization of novel platelet membrane proteins. Blood. 2009;113(19):4754–62.

96. Goubran HA, Burnouf T, Radosevic M, El-Ekiaby M. The platelet-cancer loop. Eur J Intern Med. 2013;24(5):393–400.

97. Goubran HA, Stakiw J, Radosevic M, Burnouf T. Platelets effects on tumor growth. Semin Oncol. 2014;41(3):359–69.

98. Rachidi S, Wallace K, Day TA, Alberg AJ, Li Z. Lower circulating platelet counts and antiplatelet therapy independently predict better outcomes in patients with head and neck squamous cell carcinoma. J Hematol Oncol. 2014;7:65.

99. O’Connor MN, Salles II, Cwicic A, Watkins NA, Walker A, Gerner SF, Jones CJ, Macaulay IG, Stewart M, Zwaginga JJ, De Roos P, Goodall AH, Deckmyn H, Stemple DL, Ouwehand WH, Bloedorns C. Functional genomics in zebrafish permits rapid characterization of novel platelet membrane proteins. Blood. 2009;113(19):4754–62.

100. Goubran HA, Burnouf T, Radosevic M, El-Ekiaby M. The platelet-cancer loop. Eur J Intern Med. 2013;24(5):393–400.

101. Goubran HA, Stakiw J, Radosevic M, Burnouf T. Platelets effects on tumor growth. Semin Oncol. 2014;41(3):359–69.

102. Andre P, Nannizzi-Alaimo L, Prasad SK, Phillips DR. Platelet-derived CD40L: the switch-hitting player of cardiovascular disease. Circulation. 2002;106(8):896–9.

103. Wang J, Yuan R, Song W, Sun J, Liu D, Li Z. PD-1, PD-L1 (B7-H1) and tumor-site immune modulation therapy: the historical perspective. J Hematol Oncol. 2017;10(1):34.

104. Li Z, Chen L, Rubinstein MP. Cancer immunotherapy: are we there yet? Exp Hematol Oncol. 2013;2(1):33.

105. Neuzillet C, Tijeras-Raballand A, Prasad SK, Phillips DR. Platelet-derived CD40L: the switch-hitting player of cardiovascular disease. Circulation. 2002;106(8):896–9.

106. Wang J, Yuan R, Song W, Sun J, Liu D, Li Z. PD-1, PD-L1 (B7-H1) and tumor-site immune modulation therapy: the historical perspective. J Hematol Oncol. 2017;10(1):34.

107. Li Z, Chen L, Rubinstein MP. Cancer immunotherapy: are we there yet? Exp Hematol Oncol. 2013;2(1):33.

108. Neuzillet C, Tijeras-Raballand A, Cohen R, Cros J, Faivre S, Raymond E, de Gramont A. Targeting the TGFbeta pathway for cancer therapy. Pharmacol Ther. 2015;147:22–31.

109. Connolly EC, Freimuth J, Akhurst RJ. Complexities of TGF-beta targeted cancer therapy. Int J Biol Sci. 2012;8(7):964–78.

110. Cordeiro MF, Gay JA, Khaw PT. Human anti-transforming growth factor-beta2 antibody: a new glaucoma anti-scarring agent. Invest Ophthalmol Vis Sci. 1999;40(10):2225–34.

111. Byrne WL, Mills KH, Lederer JA, O’Sullivan GC. Targeting regulatory T cells in cancer. Cancer Res. 2011;71(22):6915–20.

112. Couper KN, Lantieri PA, Perona-Wright G, Kummer LW, Chen W, Smiley ST, Mohrs M, Johnson LL. Anti-CXCL5 antibody-mediated depletion of effector T cell populations enhances susceptibility of mice to acute but not chronic toxoplasma gondii infection. J Immunol. 2009;182(7):3985–94.